Background: In December 2019, in light of additional blinded data, Biogen claimed efficacy of the drug Aducanumab (ADU). Objective: We conducted a reanalysis of the phase III ADU summary statistics, focusing in particular on the Clinical Dementia Rating-Sum of Boxes. Methods: We used a Bayesian framework to mitigate the problems of the null-hypothesis significance testing framework. In particular, we used Bayes Factor (BF) to analyze the summary statistics. The BF is the comparison of how well two hypotheses predict the data. Results: Our results showed that the evidence for ADU efficacy is very low. The results show that the only data with a BF value in favor of the alternative hypothesis (i.e., drug efficacy) is the high-dose condition in the EMERGE trial. However, the obtained BF falls within the range of values considered anecdotal, meaning a low level of evidence. Conclusion: We provide a clearer interpretation of the results of the clinical trials based on the Bayesian framework, as this may be useful for future development and research in the field.
A Bayesian Reanalysis of the Phase III Aducanumab (ADU) Trial
Tommaso Costa
First
;Franco CaudaLast
2022-01-01
Abstract
Background: In December 2019, in light of additional blinded data, Biogen claimed efficacy of the drug Aducanumab (ADU). Objective: We conducted a reanalysis of the phase III ADU summary statistics, focusing in particular on the Clinical Dementia Rating-Sum of Boxes. Methods: We used a Bayesian framework to mitigate the problems of the null-hypothesis significance testing framework. In particular, we used Bayes Factor (BF) to analyze the summary statistics. The BF is the comparison of how well two hypotheses predict the data. Results: Our results showed that the evidence for ADU efficacy is very low. The results show that the only data with a BF value in favor of the alternative hypothesis (i.e., drug efficacy) is the high-dose condition in the EMERGE trial. However, the obtained BF falls within the range of values considered anecdotal, meaning a low level of evidence. Conclusion: We provide a clearer interpretation of the results of the clinical trials based on the Bayesian framework, as this may be useful for future development and research in the field.File | Dimensione | Formato | |
---|---|---|---|
2107.03686.pdf
Accesso aperto
Descrizione: A Bayesian Reanalysis of the Phase III Aducanumab (ADU) Trial
Tipo di file:
PREPRINT (PRIMA BOZZA)
Dimensione
245.68 kB
Formato
Adobe PDF
|
245.68 kB | Adobe PDF | Visualizza/Apri |
costa-cauda-2022-a-bayesian-reanalysis-of-the-phase-iii-aducanumab-(adu)-trial.pdf
Accesso riservato
Tipo di file:
PDF EDITORIALE
Dimensione
170.26 kB
Formato
Adobe PDF
|
170.26 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.